$THC

KERREY J ROBERT sold $64K of THC

KERREY J ROBERT sold 361 shares of TENET HEALTHCARE CORP (THC) at $177.52 on 2026-05-28.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 30, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 30, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure provides incremental sentiment information but does not include new company fundamentals (no earnings, guidance, deal, or regulatory action). Traders may only adjust positioning tactically around insider-flow narratives.

02

Market read

A director’s open-market sale at a specific price is a low-signal, sentiment-only datapoint for THC.

03

What to watch

The article doesn’t state whether the sale was part of a broader planned program or for tax/estate needs; absence of a 10b5-1 plan can increase speculation but still lacks fundamental context.

Relevance 6/10Novelty 6/10Timing: Filed 2026-05-29 after sale dated 2026-05-28

Background

This is an SEC Form 4 insider transaction for Tenet Healthcare (THC), reporting an open-market sale by a director.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director KERREY J ROBERT sold 361 shares in an open-market transaction at $177.52 on 2026-05-28.

Expected impact

Likely limited/short-lived impact; any move would be sentiment-driven rather than earnings- or deal-driven.

Evidence & confidence

The filing is an ownership-change disclosure (insider sale) with no stated operational or financial trigger; size is relatively small versus typical market cap noise.

Market effects

Minimal; single-company insider sale without guidance/earnings changes is unlikely to reset sector expectations.

None indicated.

None indicated.

Counterpoint

Insider sales are often routine (tax/portfolio rebalancing) and may not reflect negative fundamentals, especially without a 10b5-1 plan disclosure.

Key entities

  • TENET HEALTHCARE CORP

    Subject of the Form 4 insider sale disclosure.

  • KERREY J ROBERT

    Director who sold 361 shares on 2026-05-28.

Related articles

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.

$THCHighAI 9/10

Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook

Tenet Healthcare (THC) reported Q2 2026 adjusted EPS of $6.12, 50% above the Zacks Consensus, with net operating revenues up 6.8% to $5.63B. Adjusted net income rose 39.3% to $514M. The company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and authorized a $2B share repurchase increase.

$THCMedAI 8/10

Why Tenet Healthcare Stock Is Soaring Today

Tenet Healthcare (THC) shares rose after the company reported fiscal Q2 results and raised 2026 guidance. For the quarter ended in June, revenue was $5.63B and adjusted EPS was $6.12, both above year-ago figures and analyst estimates ($5.43B revenue, $4.26 EPS). 2026 revenue guidance increased to $21.9B-$22.5B and adjusted EBITDA to $4.83B-$5.03B.